DEXCOM INC (DXCM) Stock Fundamental Analysis

NASDAQ:DXCM • US2521311074

72.725 USD
+2.29 (+3.26%)
Last: Feb 18, 2026, 12:35 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to DXCM. DXCM was compared to 185 industry peers in the Health Care Equipment & Supplies industry. DXCM has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. DXCM has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year DXCM was profitable.
  • In the past year DXCM had a positive cash flow from operations.
  • Of the past 5 years DXCM 4 years were profitable.
  • Of the past 5 years DXCM 4 years had a positive operating cash flow.
DXCM Yearly Net Income VS EBIT VS OCF VS FCFDXCM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

1.2 Ratios

  • DXCM has a better Return On Assets (9.61%) than 92.97% of its industry peers.
  • DXCM has a Return On Equity of 26.44%. This is amongst the best in the industry. DXCM outperforms 97.30% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 15.72%, DXCM belongs to the top of the industry, outperforming 95.68% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for DXCM is above the industry average of 8.75%.
  • The 3 year average ROIC (11.25%) for DXCM is below the current ROIC(15.72%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 9.61%
ROE 26.44%
ROIC 15.72%
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
DXCM Yearly ROA, ROE, ROICDXCM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20 30

1.3 Margins

  • With an excellent Profit Margin value of 15.96%, DXCM belongs to the best of the industry, outperforming 92.97% of the companies in the same industry.
  • DXCM's Profit Margin has improved in the last couple of years.
  • The Operating Margin of DXCM (18.41%) is better than 90.81% of its industry peers.
  • In the last couple of years the Operating Margin of DXCM has grown nicely.
  • DXCM has a Gross Margin of 60.20%. This is in the better half of the industry: DXCM outperforms 61.62% of its industry peers.
  • DXCM's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 18.41%
PM (TTM) 15.96%
GM 60.2%
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
DXCM Yearly Profit, Operating, Gross MarginsDXCM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • DXCM has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • There is no outstanding debt for DXCM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DXCM Yearly Shares OutstandingDXCM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
DXCM Yearly Total Debt VS Total AssetsDXCM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • An Altman-Z score of 5.13 indicates that DXCM is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 5.13, DXCM is doing good in the industry, outperforming 79.46% of the companies in the same industry.
  • DXCM has a debt to FCF ratio of 2.36. This is a good value and a sign of high solvency as DXCM would need 2.36 years to pay back of all of its debts.
  • DXCM has a Debt to FCF ratio of 2.36. This is amongst the best in the industry. DXCM outperforms 85.95% of its industry peers.
  • DXCM has a Debt/Equity ratio of 0.47. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.47, DXCM perfoms like the industry average, outperforming 43.78% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 2.36
Altman-Z 5.13
ROIC/WACC1.64
WACC9.57%
DXCM Yearly LT Debt VS Equity VS FCFDXCM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.3 Liquidity

  • A Current Ratio of 1.56 indicates that DXCM should not have too much problems paying its short term obligations.
  • DXCM has a Current ratio of 1.56. This is in the lower half of the industry: DXCM underperforms 71.89% of its industry peers.
  • A Quick Ratio of 1.38 indicates that DXCM should not have too much problems paying its short term obligations.
  • DXCM's Quick ratio of 1.38 is on the low side compared to the rest of the industry. DXCM is outperformed by 60.00% of its industry peers.
  • DXCM does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.56
Quick Ratio 1.38
DXCM Yearly Current Assets VS Current LiabilitesDXCM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • DXCM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.73%, which is quite good.
  • The Earnings Per Share has been growing by 19.29% on average over the past years. This is quite good.
EPS 1Y (TTM)12.73%
EPS 3Y28.82%
EPS 5Y19.29%
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%13.12%

3.2 Future

  • DXCM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.07% yearly.
  • DXCM is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.21% yearly.
EPS Next Y35.74%
EPS Next 2Y27.97%
EPS Next 3Y26.78%
EPS Next 5Y22.07%
Revenue Next Year12.62%
Revenue Next 2Y12.5%
Revenue Next 3Y12.3%
Revenue Next 5Y12.21%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
DXCM Yearly Revenue VS EstimatesDXCM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B 8B 10B
DXCM Yearly EPS VS EstimatesDXCM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 39.10, DXCM can be considered very expensive at the moment.
  • 71.89% of the companies in the same industry are more expensive than DXCM, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 27.16, DXCM is valued a bit more expensive.
  • With a Price/Forward Earnings ratio of 28.80, DXCM can be considered very expensive at the moment.
  • 72.97% of the companies in the same industry are more expensive than DXCM, based on the Price/Forward Earnings ratio.
  • DXCM is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 28.10, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 39.1
Fwd PE 28.8
DXCM Price Earnings VS Forward Price EarningsDXCM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • 72.43% of the companies in the same industry are more expensive than DXCM, based on the Enterprise Value to EBITDA ratio.
  • 83.78% of the companies in the same industry are more expensive than DXCM, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 26.71
EV/EBITDA 23.39
DXCM Per share dataDXCM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

  • DXCM's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • DXCM has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as DXCM's earnings are expected to grow with 26.78% in the coming years.
PEG (NY)1.09
PEG (5Y)2.03
EPS Next 2Y27.97%
EPS Next 3Y26.78%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for DXCM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DEXCOM INC

NASDAQ:DXCM (2/18/2026, 12:35:05 PM)

72.725

+2.29 (+3.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-12
Earnings (Next)04-29
Inst Owners99.77%
Inst Owner Change-3.55%
Ins Owners0.19%
Ins Owner Change2.63%
Market Cap28.36B
Revenue(TTM)N/A
Net Income(TTM)720.70M
Analysts84.32
Price Target87.74 (20.65%)
Short Float %3.99%
Short Ratio2.84
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.05%
Min EPS beat(2)5.32%
Max EPS beat(2)6.77%
EPS beat(4)2
Avg EPS beat(4)-0.91%
Min EPS beat(4)-11.66%
Max EPS beat(4)6.77%
EPS beat(8)6
Avg EPS beat(8)4.61%
EPS beat(12)10
Avg EPS beat(12)13.69%
EPS beat(16)11
Avg EPS beat(16)6.53%
Revenue beat(2)2
Avg Revenue beat(2)0.74%
Min Revenue beat(2)0.61%
Max Revenue beat(2)0.88%
Revenue beat(4)2
Avg Revenue beat(4)0.02%
Min Revenue beat(4)-1.2%
Max Revenue beat(4)0.88%
Revenue beat(8)2
Avg Revenue beat(8)-0.92%
Revenue beat(12)5
Avg Revenue beat(12)-0.38%
Revenue beat(16)6
Avg Revenue beat(16)-0.58%
PT rev (1m)-0.9%
PT rev (3m)-14.09%
EPS NQ rev (1m)0.61%
EPS NQ rev (3m)0.29%
EPS NY rev (1m)0.16%
EPS NY rev (3m)-0.07%
Revenue NQ rev (1m)0.24%
Revenue NQ rev (3m)0.24%
Revenue NY rev (1m)0.06%
Revenue NY rev (3m)0.04%
Valuation
Industry RankSector Rank
PE 39.1
Fwd PE 28.8
P/S 6.28
P/FCF 26.71
P/OCF 19.59
P/B 10.4
P/tB 10.81
EV/EBITDA 23.39
EPS(TTM)1.86
EY2.56%
EPS(NY)2.52
Fwd EY3.47%
FCF(TTM)2.72
FCFY3.74%
OCF(TTM)3.71
OCFY5.11%
SpS11.58
BVpS6.99
TBVpS6.73
PEG (NY)1.09
PEG (5Y)2.03
Graham Number17.1
Profitability
Industry RankSector Rank
ROA 9.61%
ROE 26.44%
ROCE 19.96%
ROIC 15.72%
ROICexc 77.75%
ROICexgc 88.6%
OM 18.41%
PM (TTM) 15.96%
GM 60.2%
FCFM 23.51%
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
ROICexc(3y)35.45%
ROICexc(5y)29.66%
ROICexgc(3y)40.94%
ROICexgc(5y)33.19%
ROCE(3y)14.28%
ROCE(5y)11.73%
ROICexgc growth 3Y55.18%
ROICexgc growth 5Y18.96%
ROICexc growth 3Y50.14%
ROICexc growth 5Y16.58%
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
F-Score5
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 2.36
Debt/EBITDA 1.2
Cap/Depr 158.02%
Cap/Sales 8.55%
Interest Coverage 250
Cash Conversion 134.63%
Profit Quality 147.34%
Current Ratio 1.56
Quick Ratio 1.38
Altman-Z 5.13
F-Score5
WACC9.57%
ROIC/WACC1.64
Cap/Depr(3y)175.34%
Cap/Depr(5y)240.83%
Cap/Sales(3y)9.32%
Cap/Sales(5y)10.84%
Profit Quality(3y)97.76%
Profit Quality(5y)73.64%
High Growth Momentum
Growth
EPS 1Y (TTM)12.73%
EPS 3Y28.82%
EPS 5Y19.29%
EPS Q2Q%0%
EPS Next Y35.74%
EPS Next 2Y27.97%
EPS Next 3Y26.78%
EPS Next 5Y22.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%13.12%
Revenue Next Year12.62%
Revenue Next 2Y12.5%
Revenue Next 3Y12.3%
Revenue Next 5Y12.21%
EBIT growth 1Y28.95%
EBIT growth 3Y30.52%
EBIT growth 5Y33.11%
EBIT Next Year73.63%
EBIT Next 3Y36.37%
EBIT Next 5Y30.37%
FCF growth 1Y112.47%
FCF growth 3Y127.88%
FCF growth 5Y36.21%
OCF growth 1Y93.75%
OCF growth 3Y30.77%
OCF growth 5Y25.76%

DEXCOM INC / DXCM FAQ

Can you provide the ChartMill fundamental rating for DEXCOM INC?

ChartMill assigns a fundamental rating of 6 / 10 to DXCM.


Can you provide the valuation status for DEXCOM INC?

ChartMill assigns a valuation rating of 5 / 10 to DEXCOM INC (DXCM). This can be considered as Fairly Valued.


Can you provide the profitability details for DEXCOM INC?

DEXCOM INC (DXCM) has a profitability rating of 8 / 10.


Can you provide the PE and PB ratios for DXCM stock?

The Price/Earnings (PE) ratio for DEXCOM INC (DXCM) is 39.1 and the Price/Book (PB) ratio is 10.4.